16588-18-4

Basic information

• Product Name: ethyl 3-nitro-4-(phenylamino)benzoate
• Synonyms: ethyl 3-nitro-4-(phenylamino)benzoate
• CAS NO: 16588-18-4
• Molecular Weight: 286.287
• Mol File: 16588-18-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: ethyl 3-nitro-4-(phenylamino)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-nitro-4-(phenylamino)benzoate(16588-18-4)
• EPA Substance Registry System: ethyl 3-nitro-4-(phenylamino)benzoate(16588-18-4)

Safety Data

• Hazardous Substances Data: 16588-18-4(Hazardous Substances Data)

Upstream product

• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 367-80-6 ethyl 4-fluoro-3-nitrobenzoate 
• 62-53-3 aniline 
• 16588-16-2 ethyl 4-chloro-3-nitrobenzoate 
• 168473-87-8 ethyl 4-bromo-3-nitrobenzoate 
• 64-17-5 ethanol 
• 16927-49-4 2-nitrodiphenylamine-4-carboxylic acid 

Downstream Products

• 1350629-02-5 ethyl 1,2-diphenyl-1H-benzo[d]imidazole-5-carboxylate 
• 1453422-08-6 ethyl 2-(4-(dimethylamino)phenyl)-1-phenyl-1H-benzo[d]-imidazole-5-carboxylate 
• 1620558-19-1 ethyl 2-(4-hydroxyphenyl)-1-phenyl-1H-benzo[d]-imidazole-5-carboxylate 
• 1620558-20-4 ethyl 1-phenyl-2-p-tolyl-1H-benzo[d]imidazole-5-carboxylate 
• 1403460-44-5 ethyl 2-(4-(trifluoromethyl)phenyl)-1-phenyl-1H-benzo[d]imidazole-5-carboxylate 
• 1620558-21-5 ethyl 2-(4-nitrophenyl)-1-phenyl-1H-benzo[d]imidazole-5-carboxylate 
• 1402422-60-9 ethyl 2-(4-chlorophenyl)-1-phenyl-1H-benzo[d]imidazole-5-carboxylate 
• 68765-57-1 ethyl 3-amino-4-(phenylamino)benzoate 
• 1398394-17-6 ethyl 2-(4-bromophenyl)-1-phenyl-1H-benzo[d]imidazole-5-carboxylate 

Relevant articles and documents

Antituberculosis agents bearing the 1,2-disubstituted benzimidazole scaffold

Abstract: The emergence of drug-resistant strains in recent years has fueled the epidemic of tuberculosis. This necessitates the development of new chemical scaffolds to curb resistant tuberculosis for effective control of this disease. In this study, we have designed and synthesized two series of benzimidazole derivatives. Their antimycobacterial activities were initially evaluated using Mycobacterium tuberculosis H37RV strains. The most potent analog (6h) was further assessed using various drug-resistant M. tuberculosis strains. This report described the importance of benzimidazoles as new antitmycobacterial agents targeting both the M. tuberculosis H37RV as well as the drug-resistant-tuberculosis strains. The trifluoromethyl group which was essential for antimycobacterial activity was also highlighted. Graphical Abstract: Two series of benzimidazole derivatives and their antimycobacterial activities were evaluated using M. tuberculosis H37RV (MTB-H37RV) strains. Compound 6h was identified as the most potent among all synthesized compounds. The most potent analog was further assessed using various drug-resistant MTB strains. In addition, the trifluoromethyl was identified as an important substitution in giving good antimycobacterial effect. [InlineMediaObject not available: see fulltext.]

Benzimidazoles as new scaffold of sirtuin inhibitors: Green synthesis, in vitro studies, molecular docking analysis and evaluation of their anti-cancer properties

Two series of novel benzimidazole derivatives were designed, synthesized and evaluated for their SIRT1 and SIRT2 inhibitory activity. Among the newly synthesized compounds, compound 4j displayed the best inhibitory activity for SIRT1 (IC50 = 54

Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models

Ferrostatin-1 (Fer-1) inhibits ferroptosis, a form of regulated, oxidative, nonapoptotic cell death. We found that Fer-1 inhibited cell death in cellular models of Huntington's disease (HD), periventricular leukomalacia (PVL), and kidney dysfunction; Fer-1 inhibited lipid peroxidation, but not mitochondrial reactive oxygen species formation or lysosomal membrane permeability. We developed a mechanistic model to explain the activity of Fer-1, which guided the development of ferrostatins with improved properties. These studies suggest numerous therapeutic uses for ferrostatins, and that lipid peroxidation mediates diverse disease phenotypes.